(Q35036165)

5 August 2017

1 reference

title

Clinical applications of FDG-PET in oncology (English)

1 reference

5 August 2017

Czernin J

1

1 reference

5 August 2017

1 January 2002

1 reference

5 August 2017

Vienna Clinical Weekly

1 reference

5 August 2017

29

1 reference

5 August 2017

5

1 reference

5 August 2017

162-170

1 reference

Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.

5 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Lymph-node dissection in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

PET and [18F]-FDG in oncology: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Positron emission tomography scanning: current and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Breast cancers invisible on mammography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Pulmonary abnormalities and PET data analysis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Staging non-small cell lung cancer with whole-body PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Detection of cancer in augmented breasts by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Positron emission tomography provides molecular imaging of biological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Staging non-small cell lung cancer by whole-body positron emission tomographic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Cost-effectiveness of PET imaging in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Breast patterns as an index of risk for developing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Pulmonary nodules: differential diagnosis using 18F-fluorodeoxyglucose single-photon emission computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Analysis of cancers missed at screening mammography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Suicide and psychiatric services

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Evaluation of the solitary pulmonary nodule by positron emission tomography imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Association between [ 18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

BI-RADS categorization as a predictor of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Preoperative staging of non-small-cell lung cancer with positron-emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

[Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose]

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Positron emission tomography in breast cancer: a clinicopathological correlation of results

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

CT of the solitary pulmonary nodule

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

Detection of extrathoracic metastases by positron emission tomography in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1563-2571.2002.02042.X

10.1046/J.1563-2571.2002.02042.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12506767